vs
AVANOS MEDICAL, INC.（AVNS）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
LiveRamp Holdings, Inc.的季度营收约是AVANOS MEDICAL, INC.的1.2倍（$212.2M vs $180.9M），LiveRamp Holdings, Inc.净利率更高（18.8% vs -0.7%，领先19.5%），LiveRamp Holdings, Inc.同比增速更快（8.6% vs 0.7%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
AVNS vs RAMP — 直观对比
营收规模更大
RAMP
是对方的1.2倍
$180.9M
营收增速更快
RAMP
高出7.9%
0.7%
净利率更高
RAMP
高出19.5%
-0.7%
两年增速更快
RAMP
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $212.2M |
| 净利润 | $-1.3M | $39.9M |
| 毛利率 | 47.5% | 71.9% |
| 营业利润率 | 1.4% | 18.6% |
| 净利率 | -0.7% | 18.8% |
| 营收同比 | 0.7% | 8.6% |
| 净利润同比 | 99.7% | 255.7% |
| 每股收益（稀释后） | $-0.02 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRAMP
| Q4 25 | $180.9M | $212.2M | ||
| Q3 25 | $177.8M | $199.8M | ||
| Q2 25 | $175.0M | $194.8M | ||
| Q1 25 | $167.5M | $188.7M | ||
| Q4 24 | $179.6M | $195.4M | ||
| Q3 24 | $170.4M | $185.5M | ||
| Q2 24 | $171.7M | $176.0M | ||
| Q1 24 | $166.1M | $171.9M |
净利润AVNSRAMP
| Q4 25 | $-1.3M | $39.9M | ||
| Q3 25 | $-1.4M | $27.4M | ||
| Q2 25 | $-76.8M | $7.7M | ||
| Q1 25 | $6.6M | $-6.3M | ||
| Q4 24 | $-397.3M | $11.2M | ||
| Q3 24 | $4.3M | $1.7M | ||
| Q2 24 | $1.8M | $-7.5M | ||
| Q1 24 | $-900.0K | $-5.4M |
毛利率AVNSRAMP
| Q4 25 | 47.5% | 71.9% | ||
| Q3 25 | 48.4% | 70.2% | ||
| Q2 25 | 52.6% | 70.1% | ||
| Q1 25 | 53.6% | 69.3% | ||
| Q4 24 | 54.6% | 71.9% | ||
| Q3 24 | 54.5% | 72.4% | ||
| Q2 24 | 55.7% | 70.6% | ||
| Q1 24 | 57.1% | 72.2% |
营业利润率AVNSRAMP
| Q4 25 | 1.4% | 18.6% | ||
| Q3 25 | 0.1% | 10.7% | ||
| Q2 25 | -42.6% | 3.7% | ||
| Q1 25 | 6.1% | -6.1% | ||
| Q4 24 | -233.0% | 7.5% | ||
| Q3 24 | 7.0% | 4.0% | ||
| Q2 24 | 3.7% | -3.0% | ||
| Q1 24 | 2.4% | -8.3% |
净利率AVNSRAMP
| Q4 25 | -0.7% | 18.8% | ||
| Q3 25 | -0.8% | 13.7% | ||
| Q2 25 | -43.9% | 4.0% | ||
| Q1 25 | 3.9% | -3.3% | ||
| Q4 24 | -221.2% | 5.7% | ||
| Q3 24 | 2.5% | 0.9% | ||
| Q2 24 | 1.0% | -4.3% | ||
| Q1 24 | -0.5% | -3.1% |
每股收益（稀释后）AVNSRAMP
| Q4 25 | $-0.02 | $0.62 | ||
| Q3 25 | $-0.03 | $0.42 | ||
| Q2 25 | $-1.66 | $0.12 | ||
| Q1 25 | $0.14 | $-0.10 | ||
| Q4 24 | $-8.64 | $0.17 | ||
| Q3 24 | $0.09 | $0.03 | ||
| Q2 24 | $0.04 | $-0.11 | ||
| Q1 24 | $-0.02 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $403.4M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $962.3M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSRAMP
| Q4 25 | $89.8M | $403.4M | ||
| Q3 25 | $70.5M | $376.9M | ||
| Q2 25 | $90.3M | $371.1M | ||
| Q1 25 | $97.0M | $420.8M | ||
| Q4 24 | $107.7M | $384.3M | ||
| Q3 24 | $89.0M | $348.4M | ||
| Q2 24 | $92.2M | $342.7M | ||
| Q1 24 | $75.8M | $368.9M |
总债务AVNSRAMP
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSRAMP
| Q4 25 | $778.2M | $962.3M | ||
| Q3 25 | $778.0M | $943.8M | ||
| Q2 25 | $776.3M | $947.8M | ||
| Q1 25 | $839.4M | $948.9M | ||
| Q4 24 | $828.5M | $957.7M | ||
| Q3 24 | $1.2B | $932.1M | ||
| Q2 24 | $1.2B | $951.9M | ||
| Q1 24 | $1.2B | $949.1M |
总资产AVNSRAMP
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $1.7B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
负债/权益比AVNSRAMP
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | — |
| 自由现金流经营现金流 - 资本支出 | $21.3M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 3.8% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | — |
8季度趋势，按日历期对齐
经营现金流AVNSRAMP
| Q4 25 | $28.2M | — | ||
| Q3 25 | $14.0M | $57.4M | ||
| Q2 25 | $6.8M | $-15.8M | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | $45.1M | ||
| Q3 24 | $23.0M | $55.6M | ||
| Q2 24 | $27.8M | $-9.3M | ||
| Q1 24 | $-8.0M | — |
自由现金流AVNSRAMP
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | $56.8M | ||
| Q2 25 | $-4.2M | $-16.2M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | $44.8M | ||
| Q3 24 | $20.0M | $55.4M | ||
| Q2 24 | $21.9M | $-9.6M | ||
| Q1 24 | $-12.1M | — |
自由现金流率AVNSRAMP
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | 28.4% | ||
| Q2 25 | -2.4% | -8.3% | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | 22.9% | ||
| Q3 24 | 11.7% | 29.8% | ||
| Q2 24 | 12.8% | -5.4% | ||
| Q1 24 | -7.3% | — |
资本支出强度AVNSRAMP
| Q4 25 | 3.8% | 0.1% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 6.3% | 0.2% | ||
| Q1 25 | 4.0% | 0.2% | ||
| Q4 24 | 2.7% | 0.1% | ||
| Q3 24 | 1.8% | 0.1% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 1.0% |
现金转化率AVNSRAMP
| Q4 25 | — | — | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | 5.35× | 32.10× | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RAMP
暂无分部数据
